Patents by Inventor Christopher Self

Christopher Self has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibacterial agents: aryl myxopyronin derivatives
    Patent number: 9592221
    Abstract: The invention provides compounds of formula Ia, Ib and Ic: and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: March 14, 2017
    Assignees: Rutgers, The State University of New Jersey, Provid Pharmaceuticals Inc.
    Inventors: Richard H. Ebright, Yon W. Ebright, Juan Shen, James Bacci, Anne-Cecile Hiebel, William Solvibile, Christopher Self, Gary Olson
  • ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES
    Publication number: 20160263083
    Abstract: The invention provides compounds of formula Ia, Ib and Ic: and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 15, 2016
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, PROVID PHARMACEUTICALS INC.
    Inventors: Richard H. EBRIGHT, Yon W. EBRIGHT, Juan SHEN, James BACCI, Anne-Cecile HIEBEL, William SOLVIBILE, Christopher SELF, Gary OLSON
  • Antibacterial agents: aryl myxopyronin derivatives
    Patent number: 9315495
    Abstract: The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: April 19, 2016
    Assignees: Rutgers, The State University of New Jersey, Provid Pharmaceuticals Inc.
    Inventors: Richard H. Ebright, Yon W. Ebright, Juan Shen, James Bacci, Anne-Cecile Hiebel, William Solvibile, Christopher Self, Gary Olson
  • Method of treating HCV infection with a small molecule CHK2 inhibitor
    Patent number: 9278089
    Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 8, 2016
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: David Waugh, Christopher Self, Guangtao Zhang, Yves Pommier, Robert H. Shoemaker, Michael Currens, John Cardellina, Andrew Jobson, George Lountos, Dominic Scudiero
  • ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES
    Publication number: 20150197512
    Abstract: The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
    Type: Application
    Filed: June 19, 2013
    Publication date: July 16, 2015
    Inventors: Richard H. Ebright, Yon W. Ebright, Juan Shen, James Bacci, Anne-Cecile Hiebel, William Solvibile, Christopher Self, Gary Olson
  • METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR
    Publication number: 20140294767
    Abstract: A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 2, 2014
    Inventors: David Waugh, Christopher Self, Guangtao Zhang, Yves Pommier, Robert H. Shoemaker, Michael Currens, John Cardellina, Andrew Jobson, George Lountos, Dominic Scudiero
  • Compositions for treatment of diseases related to activated lymphocytes
    Patent number: 7981885
    Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: July 19, 2011
    Assignee: Immune Control Inc.
    Inventors: Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
  • Methods for treatment of diseases related to activated lymphocytes
    Patent number: 7923445
    Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: April 12, 2011
    Assignee: Immune Control, Inc.
    Inventors: Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
  • Modulators of ?-amyloid peptide aggregation
    Patent number: 7803774
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: September 28, 2010
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Mark A. Findeis, Kathryn Phillips, Gary L. Olsen, Christopher Self
  • Novel Composition for Treatment of Diseases Related to Activated Lymphocytes
    Publication number: 20090275557
    Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
    Type: Application
    Filed: February 26, 2009
    Publication date: November 5, 2009
    Applicant: Immune Control, Inc.
    Inventors: Stephen Roth, Clayton Buck, Christopher Self, Gary Olson, Nallaganchu Rao
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Publication number: 20090156624
    Abstract: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 18, 2009
    Applicant: Praecis Pharmaceuticals Inc
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • KINASE ANCHOR PROTEIN MUTEINS, PEPTIDES THEREOF AND RELATED METHODS
    Publication number: 20090155846
    Abstract: A-kinase anchor protein (AKAPS) muteins, peptides thereof, and nucleic acids encoding the peptides are provided herein. Also provided are transgenic animals, cells comprising transgenes and various methods employing such peptides.
    Type: Application
    Filed: September 24, 2008
    Publication date: June 18, 2009
    Applicants: SEQUENOM, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Andreas Braun, Charles R. Cantor, Stefan M. Kammerer, Susan Taylor, Lora Burns-Hamuro, Charles Cook, Gary Olson, Christopher Self
  • Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof
    Patent number: 7439231
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: October 21, 2008
    Assignee: Provid Pharmaceuticals, Inc.
    Inventors: Gary Olson, Charles Cook, Christopher Self
  • Kinase anchor protein muteins, peptides thereof and related documents
    Patent number: 7432342
    Abstract: A-kinase anchor protein (AKAPs) muteins, peptides thereof, and nucleic acids encoding the peptides are provided herein. Also provided are transgenic animals, cells comprising transgenes and various methods employing such peptides.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: October 7, 2008
    Assignees: Sequenom, Inc., The Regents of the University of Califonia
    Inventors: Andreas Braun, Charles R. Cantor, Stefan M. Kammerer, Susan Taylor, Lora Burns-Hamuro, Charles Cook, Gary Olson, Christopher Self
  • Therapeutic agents and methods of use thereof for the treatment of melanoma
    Patent number: 7405194
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: July 29, 2008
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Novel compositions for treatment of diseases related to activated lymphocytes
    Publication number: 20080132697
    Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
    Type: Application
    Filed: August 31, 2007
    Publication date: June 5, 2008
    Applicant: Immune Control, Inc.
    Inventors: Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
  • Novel methods for treatment of diseases related to activated lymphocytes
    Publication number: 20080125415
    Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
    Type: Application
    Filed: August 31, 2007
    Publication date: May 29, 2008
    Applicant: Immune Control, Inc.
    Inventors: Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Patent number: 7348307
    Abstract: The present invention provides methods of treating a lymphoma (e.g.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: March 25, 2008
    Assignee: Praecis Pharmaceuticals Incorporated
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Sheet with camouflage pattern
    Patent number: D792713
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 25, 2017
    Assignee: W.C. Bradley/Zebco Holdings, Inc.
    Inventors: William Crawley, Robert D. Bagby, Dominick David Murphy, Christopher Self Lambert, Lawrence Tyson Magana
  • Fabric sheet with camouflage pattern
    Patent number: D859855
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: September 17, 2019
    Assignee: W.C. Bradley/Zebco Holdings, Inc.
    Inventors: William Crawley, Robert D. Bagby, Dominick David Murphy, Christopher Self Lambert, Lawrence Tyson Magana